Alemtuzumab
- PDF / 138,462 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 51 Downloads / 138 Views
1
S
Anti-glomerular basement membrane disease: case report Meyer D, et al. Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 2: 60-63, No. 1, Jan 2013. Available 803080296 from: URL: http://dx.doi.org/10.1016/j.msard.2012.07.002 - USA
»
Editorial comment: This case report was previously summarised from an abstract [see Reactions 1327 p8; 803043350]. In the current paper, the authors additionally state that the patient received two annual cycles of IV alemtuzumab 12 mg/day; 5 days at month 0, and 3 days at month 12, for a cumulative dose of 96mg.
0114-9954/10/1429-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 24 Nov 2012 No. 1429
Data Loading...
